We are the only company developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for more patients with autoimmune diseases, hematologic malignancies and genetic diseases. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics(NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported the presentation of preclinical data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. MGTA-117 and CD45-ADC Targeted Conditioning Programs ... Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to … The program's lead target is CD45, a cell surface molecule broadly expressed throughout the hematopoietic and immune systems. Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting Magenta Therapeutics (NASDAQ: ... Magenta's other ADC-based conditioning program, CD45-ADC, targets both patient HSCs and disease-causing immune cells. Portfolio Our Innovative Programs . Magenta Therapeutics : Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of AVROBIO’s investigational lentiviral gene therapies. Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to … CD45-ADC. magenta therapeutics inc: * magenta therapeutics - mgta-117 conditioning adc-based program on track for initial clinical data in 2021 * magenta therapeutics - … Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies Magenta is the only company developing targeted antibody-drug conjugates designed to precisely remove the disease-causing cells in the body without the need for chemotherapy or radiation. Magenta is working to address these challenges through its integrated portfolio of therapeutics. Meeting the need “There is a significant need for targeted conditioning regimens for a bone marrow transplant, and this is a key area of focus for Magenta,” said Michael Cooke, Ph.D., Chief Scientific Officer, Magenta Therapeutics.